Accuray Incorporated (NASDAQ:ARAY) Director Joseph E. Whitters purchased 12,500 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $2.62 per share, with a total value of $32,750.00. Following the completion of the purchase, the director now directly owns 116,780 shares of the company’s stock, valued at $305,963.60. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of NASDAQ ARAY traded up $0.16 on Friday, hitting $2.82. The company had a trading volume of 502,531 shares, compared to its average volume of 721,894. Accuray Incorporated has a 12-month low of $2.35 and a 12-month high of $5.40. The business has a 50 day moving average of $3.32 and a two-hundred day moving average of $4.00. The company has a quick ratio of 1.03, a current ratio of 1.79 and a debt-to-equity ratio of 3.21. The firm has a market capitalization of $236.15 million, a P/E ratio of -18.80 and a beta of 1.96.
Accuray (NASDAQ:ARAY) last issued its earnings results on Thursday, August 15th. The medical equipment provider reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.05). Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. The company had revenue of $117.42 million during the quarter, compared to analysts’ expectations of $116.09 million. During the same period in the previous year, the company earned ($0.01) EPS. On average, sell-side analysts anticipate that Accuray Incorporated will post -0.14 earnings per share for the current year.
Several equities research analysts have commented on ARAY shares. Royal Bank of Canada set a $4.00 price target on Accuray and gave the stock a “hold” rating in a research note on Friday, August 16th. BidaskClub lowered Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, Accuray currently has a consensus rating of “Hold” and a consensus target price of $4.47.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.